Verastem:Avutometinib联合Defactinib在三野生型LGSOC中实现18%客观缓解率及13个月中位无进展生存期

美股速递
Oct 02

Verastem公司公布数据:Avutometinib与Defactinib联合疗法在三野生型低级别浆液性卵巢癌(LGSOC)患者中,客观缓解率(ORR)达到18%,中位无进展生存期(PFS)为13个月。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10